vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on vTv Therapeutics, with six buy ratings and two sell ratings. The average 12-month price target is $55.83, well above the reported $31.31 share price.
• Recent analyst views were mixed: BTIG Research raised its target to $57, while HC Wainwright cut its target to $42; Rodman & Renshaw initiated coverage with a $67 target, and Zacks Research downgraded the stock to “strong sell.”
• vTv Therapeutics reported a quarterly loss of $1.05 per share, missing the $0.97 consensus estimate. Institutional investors own 17.51% of the company, while the stock has traded between $14.55 and $44.00 over the past year.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $55.8333.

Several brokerages have issued reports on VTVT. BTIG Research upped their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a "buy" rating in a research report on Thursday, July 16th. HC Wainwright dropped their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a "buy" rating and a $67.00 price objective on the stock. Weiss Ratings downgraded shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, Zacks Research lowered shares of vTv Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Friday, August 7th.

Institutional Trading of vTv Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics in the 4th quarter valued at about $221,000. Geode Capital Management LLC raised its stake in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after acquiring an additional 12,896 shares in the last quarter. Finally, 683 Capital Management LLC bought a new stake in vTv Therapeutics in the fourth quarter worth $731,000. Institutional investors own 17.51% of the company's stock.

vTv Therapeutics Trading Up 4.0%

VTVT opened at $31.31 on Tuesday. The company has a market cap of $123.33 million, a P/E ratio of -29.54 and a beta of 0.28. The company's 50 day moving average is $33.25 and its 200-day moving average is $34.73. vTv Therapeutics has a 1-year low of $14.55 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). On average, equities analysts forecast that vTv Therapeutics will post -2.35 EPS for the current year.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source